Cumberland Pharmaceuticals Inc.
CPIX
$5.72
-$0.14-2.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.81M | 40.40M | 39.95M | 40.74M | 39.75M |
| Total Other Revenue | 4.13M | 4.13M | 1.33M | 1.33M | 1.33M |
| Total Revenue | 41.94M | 44.52M | 41.28M | 42.07M | 41.08M |
| Cost of Revenue | 7.18M | 6.67M | 6.40M | 6.74M | 6.44M |
| Gross Profit | 34.76M | 37.85M | 34.88M | 35.34M | 34.65M |
| SG&A Expenses | 31.97M | 31.05M | 28.35M | 28.42M | 28.32M |
| Depreciation & Amortization | 4.28M | 4.03M | 4.48M | 4.55M | 4.64M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.15M | 47.31M | 44.54M | 45.06M | 44.35M |
| Operating Income | -7.21M | -2.79M | -3.26M | -2.99M | -3.27M |
| Income Before Tax | -7.36M | -2.82M | -3.38M | -2.96M | -3.32M |
| Income Tax Expenses | 38.50K | 40.30K | -39.90K | -34.20K | -28.50K |
| Earnings from Continuing Operations | -7.40 | -2.86 | -3.34 | -2.93 | -3.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.20K | 28.70K | 9.50K | -5.90K | 16.60K |
| Net Income | -7.38M | -2.84M | -3.33M | -2.93M | -3.28M |
| EBIT | -7.21M | -2.79M | -3.26M | -2.99M | -3.27M |
| EBITDA | -2.82M | 1.35M | 1.34M | 1.69M | 1.51M |
| EPS Basic | -0.49 | -0.19 | -0.23 | -0.21 | -0.24 |
| Normalized Basic EPS | -0.30 | -0.12 | -0.15 | -0.14 | -0.16 |
| EPS Diluted | -0.49 | -0.19 | -0.24 | -0.22 | -0.25 |
| Normalized Diluted EPS | -0.30 | -0.12 | -0.15 | -0.15 | -0.16 |
| Average Basic Shares Outstanding | 59.84M | 59.82M | 58.83M | 57.93M | 57.08M |
| Average Diluted Shares Outstanding | 59.84M | 60.14M | 59.15M | 58.24M | 57.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |